Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Oric Pharmaceuticals, Inc. (ORIC) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "ORIC PHARMACEUTICALS, INC. CONDENSED BALANCE SHEETS Assets Current assets: Cash, cash equivalents and short-term investments $ 264,159 $ 206,272 Prepaid expenses and other current assets 4,199 4,185 Total current assets 268,358 210,457 Long-term investments 9,575 21,951 Property and equipment, net 3,250 3,253 Other assets 10,633 11,517 Total assets $ 291,816 $ 247,178 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 3,191 $ 1,320 Accrued liabilities 11,343 14,068 Total current liabilities 14,534 15,388 Other long-term liabilities 8,483 9,439 Total liabilities 23,017 24,827 Total stockholders' equity 268,799 222,351 Total liabilities and stockholders' equity $ 291,816 $ 247,178 ORIC PHARMACEUTICALS, INC. STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Mon..."
05/08/2023 8-K Quarterly results
Docs: "ORIC PHARMACEUTICALS, INC. CONDENSED BALANCE SHEETS Assets Current assets: Cash, cash equivalents and short-term investments $ 189,629 $ 206,272 Prepaid expenses and other current assets 3,535 4,185 Total current assets 193,164 210,457 Long-term investments 19,309 21,951 Property and equipment, net 3,112 3,253 Other assets 11,063 11,517 Total assets $ 226,648 $ 247,178 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 1,930 $ 1,320 Accrued liabilities 12,937 14,068 Total current liabilities 14,867 15,388 Other long-term liabilities 8,969 9,439 Total liabilities 23,836 24,827 Total stockholders' equity 202,812 222,351 Total liabilities and stockholders' equity $ 226,648 $ 247,178 ORIC PHARMACEUTICALS, INC. STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Mo..."
03/24/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Amended and Restated Bylaws",
"Amended and Restated Bylaws"
03/16/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "ORIC PHARMACEUTICALS, INC. CONDENSED BALANCE SHEETS December 31, 2022 2021 Assets Current assets: Cash, cash equivalents and short-term investments $ 206,272 $ 236,979 Prepaid expenses and other current assets 4,185 3,543 Total current assets 210,457 240,522 Long-term investments 21,951 43,386 Property and equipment, net 3,253 2,413 Other assets 11,517 12,321 Total assets $ 247,178 $ 298,642 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 1,320 $ 1,886 Accrued liabilities 14,068 13,265 Total current liabilities 15,388 15,151 Other long-term liabilities 9,439 10,515 Total liabilities 24,827 25,666 Total stockholders' equity 222,351 272,976 Total liabilities and stockholders' equity $ 247,178 $ 298,642 ORIC PHARMACEUTICALS, INC. STATEMENTS OF OPERATIONS AND COMPR..."
01/09/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones"
12/21/2022 8-K Quarterly results
11/07/2022 8-K Quarterly results
Docs: "ORIC PHARMACEUTICALS, INC. CONDENSED BALANCE SHEETS Assets Current assets: Cash, cash equivalents and short-term investments $ 193,659 $ 236,979 Prepaid expenses and other current assets 5,026 3,543 Total current assets 198,685 240,522 Long-term investments 24,310 43,386 Property and equipment, net 3,049 2,413 Other assets 11,953 12,321 Total assets $ 237,997 $ 298,642 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 1,532 $ 1,886 Accrued liabilities 11,752 13,265 Total current liabilities 13,284 15,151 Other long-term liabilities 9,894 10,515 Total liabilities 23,178 25,666 Total stockholders' equity 214,819 272,976 Total liabilities and stockholders' equity $ 237,997 $ 298,642 ORIC PHARMACEUTICALS, INC. STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three M..."
08/11/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
03/21/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Corporate Presentation"
03/21/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update"
03/04/2022 8-K Quarterly results
01/10/2022 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones"
11/10/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"ORIC Pharmaceuticals Appoints Angie You, Ph.D., to its Board of Directors SOUTH SAN FRANCISCO and SAN DIEGO, CA - November 10, 2021 - ORIC Pharmaceuticals, Inc. , a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Angie You, Ph.D., to its board of directors. Dr. You currently serves as chief executive officer of Amunix Pharmaceuticals, Inc. “We are delighted to welcome Angie to ORIC's board of directors,” said Jacob Chacko, M.D., president and chief executive officer. “Angie's broad experience spanning venture capital, a variety of business development transactions, and public company leadership will bring valuable expertise and insight to ORIC as we continue to build and advance our pipel..."
11/08/2021 8-K Quarterly results
Docs: "ORIC PHARMACEUTICALS, INC. CONDENSED BALANCE SHEETS Assets Current assets: Cash, cash equivalents and short-term investments $ 289,519 $ 293,600 Prepaid expenses and other current assets 3,330 3,097 Total current assets 292,849 296,697 Investments, available-for-sale 6,956 — Property and equipment, net 1,825 1,981 Other assets 12,550 319 Total assets $ 314,180 $ 298,997 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 419 $ 757 Accrued liabilities 11,484 8,245 Total current liabilities 11,903 9,002 Other long-term liabilities 10,741 219 Total liabilities 22,644 9,221 Total stockholders' equity 291,536 289,776 Total liabilities and stockholders' equity $ 314,180 $ 298,997 ORIC PHARMACEUTICALS, INC. STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Months En..."
10/07/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101 in Combination with Enzalutamide and Preclinical Data on ORIC-114 at AACR-NCI-EORTC"
08/18/2021 8-K Quarterly results
08/16/2021 8-K Quarterly results
08/10/2021 8-K Quarterly results
Docs: "ORIC PHARMACEUTICALS, INC. CONDENSED BALANCE SHEETS Assets Current assets: Cash, cash equivalents and short-term investments $ 261,068 $ 293,600 Prepaid expenses and other current assets 3,884 3,097 Total current assets 264,952 296,697 Property and equipment, net 1,828 1,981 Other assets 1,447 319 Total assets $ 268,227 $ 298,997 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 838 $ 757 Accrued liabilities 9,066 8,245 Total current liabilities 9,904 9,002 Other long-term liabilities — 219 Total liabilities 9,904 9,221 Total stockholders' equity 258,323 289,776 Total liabilities and stockholders' equity $ 268,227 $ 298,997 ORIC PHARMACEUTICALS, INC. STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2..."
07/12/2021 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
07/08/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"ORIC Pharmaceuticals Announces FDA Clearance of IND Application for ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor"
06/21/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
03/23/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Licensed Exclusive Rights to EGFR/HER2 Exon 20 Inhibitor Program, ORIC-114: In October 2020, ORIC licensed from Voronoi, Inc. exclusive rights worldwide excluding the People’s Republic of China, Hong Kong, Macau and Taiwan for the development and commercialization of a potential best-in-class brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency against exon 20 insertion mutations. ORIC expects to file a Clinical Trial Application and initiate a global Phase 1/2 tumor-agnostic trial in genetically defined cancers for ORIC-114 in the second half of 2021. • Licensed Exclusive Worldwide Rights to PRC2 Inhibitor, ORIC-944: In August 2020, ORIC licensed fr..."
10/19/2020 8-K Quarterly results
08/05/2020 8-K Quarterly results
06/10/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "ORIC Pharmaceuticals Appoints Lori Kunkel, M.D., to its Board of Directors"
05/20/2020 8-K Quarterly results
Docs: "First Patient Dosed in ORIC-101 Phase 1b Combination Trial for Prostate Cancer: In January 2020, ORIC announced the dosing of its first patient in a Phase 1b clinical trial being conducted under a collaboration with Astellas Pharma, Inc., to evaluate the combination of ORIC-101 with XTANDI® as a treatment for patients with metastatic prostate cancer that is progressing on enzalutamide. This marked ORIC’s second Phase 1b clinical trial of ORIC-101, following the initiation in 2019 of a Phase 1b trial of ORIC-101 in combination with Abraxane® in patients with solid tumors. • Preclinical Data on CD73 Inhibitor Program Presented at AACR: In April 2020, ORIC presented research that led to the discovery of ORIC-533, an orally bioavailable small molecule inhibitor of CD73, at the 2020 Amer..."
04/28/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and ...
Docs: "Amended and Restated Certificate of Incorporation of the Registrant",
"Amended and Restated Bylaws of the Registrant",
"ORIC Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy